North America Anticoccidial Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 537.19 Million |
| Market Size (2029) | USD 673.61 Million |
| CAGR (2024 - 2029) | 4.63 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
North America Anticoccidial Drugs Market Analysis
The North America Anticoccidial Drugs Market size is estimated at USD 537.19 million in 2024, and is expected to reach USD 673.61 million by 2029, growing at a CAGR of 4.63% during the forecast period (2024-2029).
Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.
Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.
Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.
However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.
North America Anticoccidial Drugs Market Trends
This section covers the major market trends shaping the North America Anticoccidial Drugs Market according to our research experts:
The Ionophore Anticoccidial segment dominates the North America Anticoccidial Drugs Market
A major breakthrough in the prevention of coccidiosis through feed medication occurred in 1972, with the launch of the first polyether ionophore anticoccidial, monensin. This type of anticoccidial agent has been commonly referred to as ionophores, a term derived from their general chemical structure. Ionophores are the fermentation products of Streptomyces and other fungi species.
Furthermore, these drugs are widely used for the prevention of coccidiosis, due to its broad-spectrum activity against the majority of pathogenic species of coccidian and lack of development of drug resistance. Each has a different mode of action and no significant resistance has been developed. These drugs are commonly added to the starter and grower feeds, but not to the finisher or withdrawal feeds.
Furthermore, when the same ionophore anticoccidial is added to the starter and grower feeds, it is known as a straight program. In 2017, the US Food and Drug Administration reported that 82% of all domestic sales and distribution of non-medically important antimicrobials were from ionophores, amounting to 4,394,850 kilo gram.
As a result of the aforementioned factors, the ionophore anticoccidial segment is expected to experience healthy growth during the forecast period.
North America Anticoccidial Drugs Industry Overview
The North America Anticoccidial Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Zoetis Animal Healthcare, Phibro Animal Health Corporation, Huvepharma, Elanco, Ceva Animal Health Inc., MSD Animal Health, Vetoquinol SA, Impextraco NV.
North America Anticoccidial Drugs Market Leaders
-
Phibro Animal Health Corporation
-
Huvepharma
-
Zoetis Animal Healthcare
-
Elanco.
-
Boehringer Ingelheim GmbH
*Disclaimer: Major Players sorted in no particular order
North America Anticoccidial Drugs Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increased Incidence of Coccidiosis
-
4.2.2 Advancements in Veterinary Healthcare
-
-
4.3 Market Restraints
-
4.3.1 Availability of Alternative Treatment Options in the Market
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug Type
-
5.1.1 Ionophore Anticoccidials
-
5.1.2 Chemical Derivative Anticoccidials
-
-
5.2 By Animal
-
5.2.1 Poultry
-
5.2.2 Swine
-
5.2.3 Fish
-
5.2.4 Cattle
-
5.2.5 Companion Animals
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Zoetis Animal Healthcare
-
6.1.2 Phibro Animal Health Corporation
-
6.1.3 Huvepharma
-
6.1.4 Elanco
-
6.1.5 Ceva Animal Health Inc.
-
6.1.6 MSD Animal Health
-
6.1.7 Vetoquinol SA
-
6.1.8 Impextraco NV
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Anticoccidial Drugs Industry Segmentation
Coccidiosis is one of the most frequent and prevalent parasitic diseases among domesticated animals and its symptoms include weight loss, mild intermittent to severe diarrhoea, faeces containing mucus or blood, dehydration, and decreased breeding. Coccidiosis is caused by single-celled parasites (protozoa) called Eimeria, which undergo a simple life cycle in the gut. Any drug used to combat the progression of coccidiosis in birds or animals, both food-producing and non-food producing, is termed as an anticoccidial.
North America Anticoccidial Drugs Market Research FAQs
How big is the North America Anticoccidial Drugs Market?
The North America Anticoccidial Drugs Market size is expected to reach USD 537.19 million in 2024 and grow at a CAGR of 4.63% to reach USD 673.61 million by 2029.
What is the current North America Anticoccidial Drugs Market size?
In 2024, the North America Anticoccidial Drugs Market size is expected to reach USD 537.19 million.
Who are the key players in North America Anticoccidial Drugs Market?
Phibro Animal Health Corporation, Huvepharma, Zoetis Animal Healthcare, Elanco. and Boehringer Ingelheim GmbH are the major companies operating in the North America Anticoccidial Drugs Market.
What years does this North America Anticoccidial Drugs Market cover, and what was the market size in 2023?
In 2023, the North America Anticoccidial Drugs Market size was estimated at USD 513.42 million. The report covers the North America Anticoccidial Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Anticoccidial Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Anticoccidial Drugs Industry Report
Statistics for the 2024 North America Anticoccidial Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Anticoccidial Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
